Durable lipid-lowering beyond 10 years with lomitapide in homozygous familial hypercholesterolemia: A real-world experience in Taiwan. (PubMed, J Clin Lipidol) - Sep 10, 2026 - "Lomitapide provides durable LDL-C reduction beyond a decade with a manageable safety profile, supporting its long-term therapeutic role in East Asian patients with HoFH."
Journal • Real-world evidence • Atherosclerosis • Cardiovascular • Dyslipidemia • Familial Hypercholesterolemia • Genetic Disorders • Homozygous Familial Hypercholesterolemia • Metabolic Disorders
|
|
Chao-Feng Lin; Min-Ji Charng; Wen-Hwa Wang
|